ArticleDocumenta ophthalmologica. Advances in ophthalmology2026
Retinal electrophysiological responses to dopaminergic therapy in treatment naïve Parkinson's disease.
Article in Documenta ophthalmologica. Advances in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeParkinson's disease (PD) is a progressive neurodegenerative disorder in which the retina acts as a dopaminergic extension of the central nervous system. This study aimed to evaluate the effects of dopaminergic therapy on retinal electrophysiological responses in newly diagnosed, treatment-naïve PD patients and to compare these findings with those of healthy controls.
methodsForty eyes from 20 PD patients underwent full-field electroretinography (ffERG). Photopic a-wave, b-wave, and photopic negative response (PhNR) wave amplitudes and implicit times were recorded before and after one month of dopaminergic therapy. For comparison, one randomly selected eye from each of 20 age- and sex-matched healthy control subjects also underwent the same ffERG protocol.
resultsFollowing dopaminergic treatment, a-wave (- 6.6 ± 1.4 µV, p < 0.001), b-wave (20.0 ± 4.8 µV, p = 0.001), and PhNR wave amplitudes (- 7.9 ± 1.8 µV, p < 0.001) significantly increased. Pre-treatment, a-wave (- 8.9 ± 3.5 µV, p = 0.014), b-wave (38.3 ± 9.8 µV, p < 0.001), and PhNR-wave (- 17.6 ± 2.8 µV, p < 0.001) amplitudes were significantly lower in the PD group compared with controls. Post-treatment, a- and b-wave amplitudes became comparable to those of the control group (p > 0.05), while PhNR-wave amplitude remained significantly reduced (- 9.7 ± 4.1 µV, p = 0.023).
conclusionDopaminergic therapy significantly improved retinal electrophysiological responses in treatment-naïve PD patients. After treatment, the a- and b-wave amplitudes approached control levels, whereas the PhNR amplitude remained significantly reduced. These findings suggest that retinal dopaminergic dysfunction in PD may be partially reversible, and ffERG parameters can serve as sensitive biomarkers for monitoring treatment response.
Indexed as
Identifiers
41495563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.